GSK PLC closed 14.28% short of its 52-week high of £16.79, which the company reached on September 9th.

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute ...

C3.ai is driving growth beyond oil and gas, with rising traction in manufacturing, government and life sciences in fiscal 2025.

Recent advancements in COPD treatments are providing patients with potential new first-line treatments. Pharmaceutical ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million.

Gain insights from Mersana Therapeutics' Q2 2025 earnings call. Highlights include Emi-Le advancements in TNBC, $15M milestone, and a $77M cash position.

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

Organisations need future-ready leadership and Bella Ikpasaja FCMI has made it her life’s mission to provide it ...